Pharmaceuticals APAC

APAC Treatment-Resistant Depression Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Treatment-Resistant Depression Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $474.2 Mn Placeholder estimate
Estimate 2025 $518.8 Mn 22.2% of the global market
Projected 2034 $1.16 Bn 124.5% Adds $645.8 Mn over 9 forecast years
CAGR 2025–2034 9.4% Faster than 51% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 22.24% of the global market.
  • Among regions, the largest is North America at $1.17 Bn.
  • Fastest growing: APAC (this report) at 9.4% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$645.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Treatment-Resistant Depression Drugs Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $474.2 Mn — —
2025 (base) $518.8 Mn +$44.6 Mn —
2026 (forecast) $567.6 Mn +$48.8 Mn +9.4%
2027 (forecast) $621.0 Mn +$53.4 Mn +19.7%
2028 (forecast) $679.3 Mn +$58.4 Mn +30.9%
2029 (forecast) $743.2 Mn +$63.9 Mn +43.2%
2030 (forecast) $813.0 Mn +$69.9 Mn +56.7%
2031 (forecast) $889.5 Mn +$76.4 Mn +71.4%
2032 (forecast) $973.1 Mn +$83.6 Mn +87.6%
2033 (forecast) $1.06 Bn +$91.5 Mn +105.2%
2034 (forecast) $1.16 Bn +$100.1 Mn +124.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Treatment-Resistant Depression Drugs Market Analysis at a glance
Market size, 2025$518.8 Mn placeholder estimate
Forecast, 2034$1.16 Bn placeholder estimate
Growth (CAGR), 2025–20349.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route and end user (see all)
Key playersJohnson & Johnson, AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Axsome Therapeutics, Compass Pathways (see all)
Active clinical trials10 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Treatment-Resistant Depression Drugs Market Analysis Executive Summary

Treatment-resistant depression drugs help people whose depression has not improved with at least two standard antidepressants.

Key segments of the treatment-Resistant Depression Drugs market include drug class (NMDA Antagonists, Atypical Antipsychotic Add-Ons and Psychedelics) and route (Oral, Intranasal and Intravenous).

Bar chart: Asia Pacific Treatment-Resistant Depression Drugs market size, 2024–2034, placeholder estimates. $474.2 Mn in 2024, $518.8 Mn in 2025 and $1.16 Bn in 2034, 9.4% CAGR.
Asia Pacific Treatment-Resistant Depression Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Treatment-Resistant Depression Drugs Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the treatment-Resistant Depression Drugs market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the treatment-Resistant Depression Drugs market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the treatment-Resistant Depression Drugs market.

Competitive Landscape for Treatment-Resistant Depression Drugs Market in APAC

The treatment-Resistant Depression Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Treatment-Resistant Depression Drugs Market in APAC

Treatment-Resistant Depression Drugs in APAC: rules, payment and research

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20]. ClinicalTrials.gov lists 10 studies on Treatment-Resistant Depression Drugs that are recruiting, active or about to start in APAC.⁠[21]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

[21] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for treatment-Resistant Depression Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Treatment-Resistant Depression Drugs right now, from free public sources.

Clinical trials

10 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Motif Neurotech, Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)
  2. LivaNova PLC 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Suicide rate, per 100,000 people (WHO)
CountryValueYear
Afghanistan3.32023
Australia13.22023
Bangladesh4.32023
China7.92023
India14.02023
Indonesia1.82023
Japan16.52023
Malaysia4.12023
Myanmar3.82023
Nepal14.02023
New Zealand13.42023
Pakistan7.32023
Philippines2.82023
Singapore7.62023
Thailand10.32023
Compare every country on the Public Health Dashboard

Latest research 3,145 papers since 2021 (worldwide)

  1. Nogo-related frontal theta-band activity after magnetic seizure therapy in treatment-resistant depression: an exploratory task-based EEG study. Frontiers in psychiatry, 2026
  2. Ketamine for Treatment-Resistant Depression. Journal of the American Psychiatric Nurses Association, 2026
  3. From Rapid Synaptic Events to Lasting Antidepressant States: Convergent and Divergent Mechanisms of Ketamine and Psychedelics. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2026
  4. Treatment-Resistant Depression Is Not a Single Disorder. Journal of psychiatric practice, 2026
  5. Treatment-Resistant Depression. Journal of psychiatric practice, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Treatment-Resistant Depression Drugs in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Treatment-Resistant Depression Drugs market in Asia Pacific?
Placeholder estimate: about $518.8 Mn in 2025, rising to about $1.16 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Treatment-Resistant Depression Drugs market in Asia Pacific growing?
Placeholder estimate: about 9.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Treatment-Resistant Depression Drugs market report cover?
The report splits the market by drug class (NMDA Antagonists, Atypical Antipsychotic Add-Ons, Psychedelics, Others), route (Oral, Intranasal, Intravenous) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Treatment-Resistant Depression Drugs market?
Key players include Johnson & Johnson, AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Axsome Therapeutics and Compass Pathways.
What is driving the Treatment-Resistant Depression Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the treatment-Resistant Depression Drugs market. Governments and employers are investing more in mental health care.
How many clinical trials on Treatment-Resistant Depression Drugs are running in Asia Pacific?
10 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Treatment-Resistant Depression Drugs?
PubMed lists 3,145 papers on Treatment-Resistant Depression Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on mental health

See the topic